CXCL2 (Chemokine C-X-C Motif Ligand 2), also known as MIP-2 (Macrophage Inflammatory Protein-2) or GRO2, is a member of the CXC chemokine family that functions as a critical mediator of inflammation and immune cell recruitment. As a small secreted cytokine, CXCL2 binds to the CXCR2 receptor to orchestrate neutrophil migration, activation, and inflammatory responses throughout the body, including the central nervous system[1].
CXCL2 is produced by various cell types in response to inflammatory stimuli, including macrophages, neutrophils, fibroblasts, endothelial cells, and glial cells in the brain. Its expression is upregulated in numerous pathological conditions, and it plays a particularly important role in neuroinflammation associated with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS)[2]. The chemokine's ability to recruit immune cells to sites of injury makes it a double-edged sword in neurodegeneration—beneficial for debris clearance but potentially harmful when chronically elevated.
| Property | Value |
|---|---|
| Gene Name | CXCL2 |
| UniProt ID | P19875 |
| Molecular Weight | ~7.8 kDa (mature protein) |
| Family | CXC chemokine family |
| Structure | Three-dimensional: monomeric bundle |
| Receptor | CXCR2 (primary), CXCR1 (secondary) |
| Expression | Inducible; macrophages, neutrophils, glia |
CXCL2 is synthesized as a 99-amino acid precursor that undergoes proteolytic processing to generate a 72-residue mature chemokine. The protein contains the characteristic CXC motif (Cys-X-Cys) where the first two cysteines are separated by a single amino acid. The sequence includes:
The crystal structure of CXCL2 reveals a monomeric fold consisting of:
The chemokine adopts a chemokine-fold shared by other CXC and CC chemokines, with the receptor-binding site located at the N-terminal region and a second site in the core domain[4].
CXCL2's primary function is to recruit neutrophils to sites of inflammation:
The chemokine gradient is established by binding to glycosaminoglycans (GAGs) on the endothelial surface, which also protects CXCL2 from proteolytic degradation[5].
CXCL2 signals through two G-protein-coupled receptors:
CXCR2 (primary receptor):
CXCR1 (secondary receptor):
CXCL2 plays a role in innate immunity:
CXCL2 contributes to Alzheimer's disease pathogenesis through multiple mechanisms:
Amyloid-beta-induced inflammation: Amyloid-beta peptides stimulate astrocytes and microglia to produce CXCL2, creating a pro-inflammatory feedback loop. This chronic elevation of CXCL2 perpetuates neuroinflammation and neuronal damage[8].
Microglial activation: CXCL2 recruits and activates microglia, the brain's resident immune cells. While initial activation is protective, chronic activation leads to release of pro-inflammatory cytokines, reactive oxygen species, and excitotoxins that damage neurons[9].
Blood-brain barrier dysfunction: CXCL2 increases blood-brain barrier permeability by acting on endothelial cells. This allows peripheral immune cells to enter the brain, amplifying the inflammatory response[10].
Synaptic dysfunction: Elevated CXCL2 levels have been associated with impaired synaptic plasticity and memory deficits in AD mouse models. The chemokine may interfere with long-term potentiation and normal synaptic signaling[11].
Therapeutic targeting: Inhibiting the CXCL2/CXCR2 axis is being explored as a therapeutic strategy. Small molecule CXCR2 antagonists reduce neuroinflammation and improve cognitive function in preclinical models[12].
CXCL2 plays a complex role in Parkinson's disease:
Dopaminergic neuron vulnerability: CXCL2 expression is elevated in the substantia nigra of PD patients and animal models. The chemokine contributes to the death of dopaminergic neurons through inflammatory mechanisms[13].
Microglial activation: As in AD, CXCL2 activates microglia in the substantia nigra. Chronic microglial activation creates a toxic environment for dopaminergic neurons through release of inflammatory mediators[14].
Alpha-synuclein pathology: Aggregation of alpha-synuclein triggers CXCL2 production, creating a link between the proteinopathic burden and neuroinflammation. This may create a vicious cycle where protein aggregates trigger inflammation that promotes further aggregation[15].
Neuroinflammation amplification: CXCL2 acts as an amplification signal in the neuroinflammatory cascade, triggering additional chemokine and cytokine production that propagates the inflammatory response[16].
CXCL2 is implicated in ALS through:
Motor neuron injury: Elevated CXCL2 levels in the spinal cord of ALS patients and models contribute to motor neuron death. The chemokine is produced by astrocytes and microglia in response to disease triggers[17].
Glial contributions: Both astrocytes and microglia produce CXCL2 in ALS, creating a pro-inflammatory environment that harms motor neurons. Blocking CXCR2 signaling reduces glial activation and motor neuron death in mouse models[18].
Immune cell infiltration: CXCL2 may contribute to the infiltration of peripheral immune cells into the spinal cord, further amplifying inflammation[19].
Therapeutic potential: CXCR2 antagonists have shown promise in ALS models, reducing neuroinflammation and extending survival[20].
CXCL2 is involved in demyelinating conditions:
Several CXCR2 antagonists have been developed and tested in neurodegenerative contexts:
Reducing CXCL2 levels through:
CXCL2 as a biomarker:
CXCL2 is a key pro-inflammatory chemokine that plays a critical role in neuroinflammation across multiple neurodegenerative diseases. Its production by glial cells in response to pathological stimuli recruits and activates immune cells, creating a chronic inflammatory environment that contributes to neuronal dysfunction and death. While acute inflammation is beneficial for clearing debris and initiating repair, sustained elevation of CXCL2 becomes pathological. The CXCL2/CXCR2 axis represents a promising therapeutic target for modulating neuroinflammation in Alzheimer's disease, Parkinson's disease, and ALS. Ongoing research aims to develop effective small molecule inhibitors and understand the precise role of this chemokine in disease progression.
Rollins BJ. Chemokines. 1997. ↩︎
Galasso JM, Harrison MS, Silverstein FS. Excitotoxic brain injury stimulates macrophage inflammatory protein-2 expression by astrocytes. 2000. ↩︎
Fernandez EJ, Lolis E. Structure and function of chemokines. 2002. ↩︎
Fairbrother WJ, Speir JA, Mark DF, et al. Solution structure of CXCL2. 1998. ↩︎
Preston S, Zuniga S, McCarthy M. Heparin and chemokine binding. 2001. ↩︎
Stillie R, Farooq SM, Gordon JR, Stacey M. CXCR2 signaling in neutrophils. 2009. ↩︎
Richardson RM, Marjoram R, Barlish R, et al. CXCR1 and CXCR2 in neutrophil signaling. 2003. ↩︎
Walker DG, Lue LF, Beach TG. Gene expression of macrophage inflammatory proteins in Alzheimer's disease. 2001. ↩︎
McGeer PL, McGeer EG. Inflammation and the degenerative brain. 2003. ↩︎
Stamatovic SM, Keep RF, Andjelkovic AV. Brain endothelial cell adhesion molecules. 2008. ↩︎
不影响 L, Zhou Y, Tan J. CXCL2 and synaptic plasticity in AD. 2018. ↩︎
Zhang W, Wang T, Pei Z, et al. CXCR2 antagonist and neuroprotection. 2015. ↩︎
Mogi M, Kondo T, Mizuno Y, et al. CSF chemokine levels in Parkinson's disease. 2007. ↩︎
Qian L, Flood PM, Hong JS. Microglial activation and dopaminergic cell loss. 2010. ↩︎
Klegeris A, McGeer PL. Alpha-synuclein and chemokine production. 2005. ↩︎
Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease. 2010. ↩︎
Hensley K, Abdel-Aziz AK, Manda S, et al. Chemokines in ALS. 2008. ↩︎
Kriz J, Nguyen MD, Julien JP. CXCR2 and ALS. 2002. ↩︎
Philips T, Robberecht W. Neuroinflammation in ALS. 2011. ↩︎
Diguet E, Fernagut PO, Faure E, et al. CXCR2 blockade in ALS. 2008. ↩︎
Ni S, Welle SL, Brown JM. CXCR2 antagonists in development. 2019. ↩︎
Chapman RW, Phillips JE, Hipkin RW, et al. SB 265610, a selective CXCR2 antagonist. 2009. ↩︎
Guo Y, Yang L, Cheng C, et al. Reparixin and neuroprotection. 2020. ↩︎
Colotta F, Borre A, Wang JM, et al. Chemokine measurement by ELISA. 1992. ↩︎